Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James W Denham

Showing results (61-70 of 92) with videos related to

Pageof 10
Sort By:
Physics in Medicine and Biology|March 25, 2015
MRI simulation: end-to-end testing for prostate radiation therapy using geometric pelvic MRI phantomsJidi Sun, Jason Dowling, Peter Pichler, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 27, 2013
Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancerJames W Denham, Allison Steigler, Keen-Hun Tai, et al.
Prostate Cancer|January 16, 2013
Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 TrialAllison Steigler, James W Denham, David S Lamb, et al.
Cancer|April 21, 2015
The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancerLaurien M Buffart, Robert U Newton, Mai J Chinapaw, et al.
The Lancet. Oncology|March 29, 2011
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trialJames W Denham, Allison Steigler, David S Lamb, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2009
Measuring time to biochemical failure in the TROG 96.01 trial: when should the clock start ticking?James W Denham, Allison Steigler, Mahesh Kumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctionsAnthony V D'Amico, James W Denham, Juanita Crook, et al.
Scientific Reports|April 2, 2021
Tumor innervation and clinical outcome in pancreatic cancerAysha Ferdoushi, Nathan Griffin, Mark Marsland, et al.
The Lancet. Oncology|October 22, 2008
Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trialJames W Denham, Allison Steigler, Chantelle Wilcox, et al.
The Lancet. Oncology|September 1, 2005
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trialBryan H Burmeister, B Mark Smithers, Val Gebski, et al.
Pageof 10

Showing results (61-70 of 92) with videos related to

Sort By:
Pageof 10
Physics in Medicine and Biology|March 25, 2015
MRI simulation: end-to-end testing for prostate radiation therapy using geometric pelvic MRI phantomsJidi Sun, Jason Dowling, Peter Pichler, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 27, 2013
Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancerJames W Denham, Allison Steigler, Keen-Hun Tai, et al.
Prostate Cancer|January 16, 2013
Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 TrialAllison Steigler, James W Denham, David S Lamb, et al.
Cancer|April 21, 2015
The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancerLaurien M Buffart, Robert U Newton, Mai J Chinapaw, et al.
The Lancet. Oncology|March 29, 2011
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trialJames W Denham, Allison Steigler, David S Lamb, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2009
Measuring time to biochemical failure in the TROG 96.01 trial: when should the clock start ticking?James W Denham, Allison Steigler, Mahesh Kumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctionsAnthony V D'Amico, James W Denham, Juanita Crook, et al.
Scientific Reports|April 2, 2021
Tumor innervation and clinical outcome in pancreatic cancerAysha Ferdoushi, Nathan Griffin, Mark Marsland, et al.
The Lancet. Oncology|October 22, 2008
Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trialJames W Denham, Allison Steigler, Chantelle Wilcox, et al.
The Lancet. Oncology|September 1, 2005
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trialBryan H Burmeister, B Mark Smithers, Val Gebski, et al.
Pageof 10